TABLE 1.
Characteristics of the patients
| Parametera | Mean value ± SD (range) or no. (%) of patients, unless otherwise indicated |
|---|---|
| No. of patients | 133 |
| Male/female | 83 (62.4)/50 (37.6) |
| Age (yr) | 47.8 ± 8.9 (28–73) |
| BMI (kg/m2) | 25.3 ± 4.0 (17.64–37.83) |
| ALAT (IU/liter; ULN, 35 IU/liter) | 109.7 ± 74.3 (18–459) |
| ASAT (IU/liter; ULN, 30 IU/liter) | 68.3 ± 47.6 (15–323) |
| GGT (IU/liter; ULN, 60 IU/liter) | 84.1 ± 81.8 (7–411) |
| Total cholesterol (mmol/liter) | 4.6 ± 1.2 (1.5–7.4) |
| Glycemia (mmol/liter) | 5.2 ± 1.2 (3.2–13.6) |
| Median viral load (log IU/ml) ± SD (range) | 5.5.± 0.7 (3.3–6.6) |
| HCV genotype | |
| 1 | 80 (60.2) |
| 2 | 12 (9.1) |
| 3 | 14 (10.5) |
| 4 | 25 (18.8) |
| 5 | 1 (0.7) |
| 6 | |
| Unknown | 1 (0.7) |
| IFNL3 rs12979860 genotype | |
| C/C | 38 (28.5) |
| C/T | 51 (38.3) |
| T/T | 29 (21.8) |
| Unknown | 15 (11.4) |
| Stage of fibrosisb | |
| F1 | 39 (29.3) |
| F2 | 50 (37.6) |
| F3 | 23 (17.3) |
| F4 | 19 (14.3) |
| unknown | 2 (1.5) |
| Treatment response | |
| SVR | 66 (49.6) |
| NR | 43 (32.3) |
| RR | 21 (15.8) |
| pNR | 47 (35.3) |
| cEVR | 63 (47.4) |
a
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; GGT, gamma-glutamyl-transferase; BMI, body mass index; ULN, upper limit of normal; SVR, sustained virological response; NR, nonresponse; RR, relapse; pNR, primary nonresponse; cEVR, complete early virological response.
b
The Metavir system was used to determine fibrosis.